Sort
51,593 grants matching “hepatitis”
Cell Cycle Control of Restenosis by apoE
$497,630Richard Assoian · University Of Pennsylvania · P01 · FY2012 · HL
Role of Neutralizing Antibodies in Transmission of SHIV
$497,587Nancy Logan Haigwood · Oregon Health & Science University · R01 · FY2009 · HD
Extracellular regulation of lipoprotein lipase activity
$497,545Ira Jay Goldberg · New York University School Of Medicine · R01 · FY2015 · HL
Novel insulin-sensitizing NASH/diabetes drugs.
$497,526Timothy R Peterson · Bioio, Llc · R42 · FY2022 · DK
Novel insulin-sensitizing NASH/diabetes drugs.
$497,526Timothy R Peterson · Bioio, Llc · R42 · FY2021 · DK
Novel insulin-sensitizing NASH/diabetes drugs.
$497,526Timothy R Peterson · Bioio, Llc · R42 · FY2020 · DK
Immune regulation and co-stimulation in treatment outcome of chronic hepatitis B
$497,497Kyong-Mi Chang · University Of Pennsylvania · U01 · FY2013 · DK
Non-esterified fatty acids and dementia: risk, structure, and biomarkers
$497,488Luc Djousse · Brigham And Women'S Hospital · R01 · FY2018 · AG
Scavenger Receptors: Ligand Binding and Pathophysiology
$497,466Monty Krieger · Massachusetts Institute Of Technology · R01 · FY2009 · HL
Durability of HBV DNA Suppression in Cirrhotics After Stopping Therapy
$497,444Harry Janssen · University Health Network · U01 · FY2012 · DK
Investigation of management and disease manifestations of viral hepatitis
$497,441Theo Heller · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Mechanisms of Venous Thromboembolism in Cancer
$497,330Nigel Mackman · Univ Of North Carolina Chapel Hill · R01 · FY2008 · HL
Lipase Expression and its Role in the Metabolic Syndrome.
$497,316Howard Wong · University Of California Los Angeles · P01 · FY2007 · HL
The role of matrix-bound microvesicles in alcohol-related liver disease
$497,269Melanie J. Scott · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AA
Malaria Vaccine Based on Self-Assembling Polypeptide Nanoparticles (SAPN)
$497,236Peter Burkhard · University Of Connecticut Storrs · R01 · FY2010 · AI
Integrative Role of Bilirubin on Obesity
$497,217David E Stec · University Of Mississippi Med Ctr · R01 · FY2021 · DK
Integrative Role of Bilirubin on Obesity
$497,217David E Stec · University Of Mississippi Med Ctr · R01 · FY2022 · DK
Integrative Role of Bilirubin on Obesity
$497,217David E Stec · University Of Mississippi Med Ctr · R01 · FY2023 · DK
Pathophysiologic mechanisms leading to intrahepatic fat accumulation in obese youth
$497,203Nicola Santoro · University Of Kansas Medical Center · R01 · FY2022 · MD
Comparing Brief Alcohol Interventions for HIV-HCV Co-infected Persons
$497,195Michael D Stein · Butler Hospital (Providence, Ri) · R01 · FY2016 · AA
The National Drug Abuse Treatment Clinical Trials Network
$497,172Walter Nmn Ling · University Of California Los Angeles · U10 · FY2011 · DA
MERS coronavirus: antagonism of double-stranded RNA induced host response by accessory proteins
$497,163Susan R. Weiss · University Of Pennsylvania · R01 · FY2018 · AI
Perinatal Per- and Polyfluoroalkyl Substances (PFAS) exposure and Immunotoxicity in early life
$497,150Liping Feng · Duke University · R01 · FY2025 · ES
Scavenger Receptors: Ligand Binding and Pathophysiology
$497,122Monty Krieger · Massachusetts Institute Of Technology · R01 · FY2011 · HL
Renal Disposition in NASH
$497,068Nathan J Cherrington · University Of Arizona · R01 · FY2019 · ES